## Antonio Grieco

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2655394/publications.pdf

Version: 2024-02-01

109 papers 5,706 citations

94381 37 h-index 79644 73 g-index

109 all docs

109 docs citations

109 times ranked 8680 citing authors

#	Article	IF	Citations
1	Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009, 49, 1877-1887.	3.6	1,138
2	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease, 2015, 47, 997-1006.	0.4	368
3	The Liver May Act as a Firewall Mediating Mutualism Between the Host and Its Gut Commensal Microbiota. Science Translational Medicine, 2014, 6, 237ra66.	5.8	365
4	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology, 2011, 54, 2055-2063.	3.6	321
5	Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 778-786.	1.8	209
6	Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biology and Medicine, 2012, 52, 1658-1665.	1.3	201
7	The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2008, 135, 282-291.e1.	0.6	177
8	Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Digestive and Liver Disease, 2014, 46, 556-560.	0.4	142
9	Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk. Current Cardiology Reports, 2015, 17, 120.	1.3	125
10	Hepatic Mitochondrial Beta-Oxidation in Patients With Nonalcoholic Steatohepatitis Assessed by 13C-Octanoate Breath Test. American Journal of Gastroenterology, 2003, 98, 2335-2336.	0.2	115
11	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e87523.	1.1	112
12	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology, 2015, 62, 784-791.	3.6	110
13	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 2011, 54, 1244-1249.	1.8	107
14	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World Journal of Gastroenterology, 2019, 25, 4814-4834.	1.4	101
15	Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target. Current Pharmaceutical Design, 2013, 19, 5314-5324.	0.9	98
16	Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review. World Journal of Gastroenterology, 2013, 19, 7867.	1.4	90
17	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1046-1054.	3.6	89
18	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85

#	Article	IF	Citations
19	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 995-1001.	1.8	61
20	A "systems medicine―approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
21	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Digestive and Liver Disease, 2015, 47, 242-248.	0.4	53
22	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. DMM Disease Models and Mechanisms, 2015, 8, 1037-46.	1.2	52
23	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e41183.	1.1	51
24	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2016, 17, 1225.	1.8	50
25	Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2019, 25, 509-520.	1.4	50
26	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World Journal of Hepatology, 2017, 9, 352.	0.8	50
27	Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGFâ€l levels. Clinical Endocrinology, 2012, 77, 531-536.	1.2	49
28	Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Current Pharmaceutical Design, 2013, 19, 5314-24.	0.9	49
29	Longâ€ŧerm metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clinical Endocrinology, 2011, 75, 520-527.	1.2	46
30	Acute hepatitis caused by a natural lipid-lowering product: When "alternative―medicine is no "alternative―at all. Journal of Hepatology, 2009, 50, 1273-1277.	1.8	43
31	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	1.3	43
32	Acute Cholestatic Hepatitis Associated with Celecoxib. Annals of Pharmacotherapy, 2002, 36, 1887-1889.	0.9	41
33	Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Translational Research, 2007, 149, 114-125.	2.2	41
34	Abdominal Angina. American Journal of the Medical Sciences, 2009, 338, 389-395.	0.4	41
35	A case–control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease. Genes and Nutrition, 2014, 9, 383.	1.2	41
36	Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterology Research and Practice, 2015, 2015, 1-5.	0.7	40

#	Article	IF	CITATIONS
37	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. International Journal of Molecular Sciences, 2021, 22, 6485.	1.8	40
38	Faecal calprotectin concentrations in untreated coeliac patients. Scandinavian Journal of Gastroenterology, 2007, 42, 957-961.	0.6	39
39	Prenatal exposure to ethanol in rats: Effects on liver energy level and antioxidant status in mothers, fetuses, and newborns. Alcohol, 1997, 14, 569-573.	0.8	38
40	Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Translational Research, 2009, 154, 194-201.	2.2	37
41	Severe Acute Hepatitis After Resumption of Interferon-Beta Therapy for Multiple Sclerosis: A Word of Caution. American Journal of Gastroenterology, 2007, 102, 2606-2607.	0.2	29
42	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs, 2021, 35, 861-880.	2.7	29
43	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. American Journal of Transplantation, 2022, 22, 1191-1200.	2.6	29
44	Recurrent Acute Hepatitis Associated with Use of Cetirizine. Annals of Pharmacotherapy, 2004, 38, 1844-1847.	0.9	28
45	Role of the "Immersion Technique―in Diagnosing Celiac Disease With Villous Atrophy Limited to the Duodenal Bulb. Journal of Clinical Gastroenterology, 2007, 41, 571-575.	1.1	27
46	Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting. International Journal of Biological Markers, 2017, 32, 397-402.	0.7	27
47	Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 1512-1519.	0.2	26
48	Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain and Behavior, 2018, 8, e00968.	1.0	24
49	Correlates of HCV seropositivity among familial contacts of HCV positive patients. BMC Public Health, 2006, 6, 237.	1.2	21
50	A case–control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. Molecular Biology Reports, 2012, 39, 7381-7388.	1.0	21
51	A phase II study of sunitinib in advanced hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 692-698.	0.4	21
52	Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Translational Research, 2021, 231, 24-38.	2.2	21
53	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology, 2018, 17, 110-118.	0.6	20
54	Intrafamilial transmission of hepatitis C virus in Italy: a systematic review. Journal of Epidemiology and Community Health, 2010, 64, 843-848.	2.0	18

#	Article	IF	Citations
55	Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 460-466.	1.4	17
56	Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. Digestive and Liver Disease, 2012, 44, 674-680.	0.4	17
57	The Effect of <i>CYP, GST, </i> and <i>SULT </i> Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma. BioMed Research International, 2015, 2015, 1-7.	0.9	17
58	Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 150-155.	0.9	17
59	Sarcoâ€Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation. Liver International, 2021, 41, 1629-1640.	1.9	17
60	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. World Journal of Gastroenterology, 2014, 20, 8158.	1.4	17
61	Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. European Journal of Gastroenterology and Hepatology, 2001, 13, 973-975.	0.8	16
62	Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Digestive and Liver Disease, 2012, 44, 1032-1036.	0.4	16
63	High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 1303-1306.	0.9	15
64	Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners. BMC Infectious Diseases, 2007, 7, 100.	1.3	15
65	A Role for the Biological Clock in Liver Cancer. Cancers, 2019, 11, 1778.	1.7	14
66	Outcomes of Liver Transplant for Adults With Wilson's Disease. Liver Transplantation, 2020, 26, 507-516.	1.3	12
67	High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study. Frontiers in Neurology, 2020, 11, 394.	1.1	12
68	Acute fatty liver after malaria prophylaxis with mefloquine. Lancet, The, 1999, 353, 295-296.	6.3	11
69	Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 1026-1030.	0.8	11
70	Peginterferon ??-2a and ribavirin versus peginterferon ??-2a monotherapy in early virological responders and peginterferon ??-2a and ribavirin versus peginterferon ??-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in na??ve patients with chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2008, 20, 680-687.	0.8	11
71	Severe Cholestatic Hepatitis due to Temozolomide. Medicine (United States), 2015, 94, e476.	0.4	11
72	Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepato-Gastroenterology, 2003, 50, 207-12.	0.5	11

#	Article	IF	CITATIONS
73	Liver Transplantation in Patients with Alcoholic Liver Disease: A Retrospective Study. Alcohol and Alcoholism, 2018, 53, 151-156.	0.9	10
74	Evaluation of the albumin-gamma-glutamyltransferase isoenzyme as a diagnostic marker of hepatocellular carcinoma-complicating liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 288-295.	1.4	9
75	Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Internal and Emergency Medicine, 2016, 11, 3-10.	1.0	9
76	Severe venoâ€occlusive disease after autologous peripheral blood stem cell transplantation for highâ€grade nonâ€Hodgkin lymphoma: report of a successfully managed case and a literature review of venoâ€occlusive disease. Clinical Transplantation, 2008, 22, 837-841.	0.8	8
77	Clopidogrel-Induced Neutropenia after Coronary Stenting: Is Cilostazol a Good Alternative?. International Journal of Vascular Medicine, 2011, 2011, 1-5.	0.4	8
78	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2103-2110.	1.1	7
79	Effect of liver transplantation on intestinal permeabilityÂand correlation with infection episodes. PLoS ONE, 2020, 15, e0235359.	1.1	7
80	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. Digestive Diseases, 2020, 38, 522-533.	0.8	7
81	The role of elastography in non-alcoholic fatty liver disease. Minerva Gastroenterology, 2021, 67, 164-170.	0.3	7
82	5-Flugrouracil (FU) and mitomycin c (MMC) in the management of colorectal carcinoma. part ii.in vitro activity of the two drugs in short term tumor cultures. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 75-78.	1.0	7
83	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Scientific Reports, 2019, 9, 585.	1.6	6
84	Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). Digestive and Liver Disease, 2021, 53, 1451-1457.	0.4	6
85	COVIDâ€19, adaptative immune response and metabolicâ€associated liver disease. Liver International, 2021, 41, 2560-2577.	1.9	6
86	Ketoalkalosis as a result of triple derangement of acid-base equilibrium in a diabetic patient. Acta Diabetologica Latina, 1985, 22, 71-77.	0.2	5
87	Comment to "Liver Match: A prospective observational cohort study on liver transplantation in Italy― Digestive and Liver Disease, 2011, 43, 921.	0.4	5
88	Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World Journal of Gastroenterology, 2011, 17, 3126-32.	1.4	5
89	Liver resection for hepatocellular carcinoma in patient with situs inversus viscerum. Updates in Surgery, 2014, 66, 91-92.	0.9	4
90	A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance. Acta Diabetologica, 2014, 51, 151-153.	1,2	4

#	Article	IF	Citations
91	Massive hepatomegaly following splenectomy for myeloid metaplasia. American Journal of Medicine, 1988, 84, 797.	0.6	3
92	Corrigendum to "Acute hepatitis caused by a natural lipid-lowering product: When "alternative― medicine is no "alternative―at all―[J Hepatol 50 (2009) 1273–1277]. Journal of Hepatology, 2010, 52, 4	66: <sup>8</sup>	3
93	5-Fluorouracil (FU) with folinic acid (FA) and mitomycin c (MMC) in the adjuvant treatment of colorectal carcinoma. part i. evaluation of toxicity. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 69-73.	1.0	3
94	Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers, 2021, 13, 6337.	1.7	3
95	Hepatic mitochondrial beta-oxidation assessment in healthy subjects by sodium 13C-octanoate breath test. Gastroenterology, 2000, 118, A924-A925.	0.6	2
96	Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2013, 25, 1001-1002.	0.8	2
97	Watery stools and metabolic acidosis. Internal and Emergency Medicine, 2017, 12, 487-492.	1.0	2
98	Role of Immunoscintigraphy in Clinical Assessment of Gastrointestinal Tumors. Tumori, 1990, 76, 270-273.	0.6	1
99	Braised Liver With Herbs: The Risks of Naturopathic Hepatoprotection. Journal of Clinical Gastroenterology, 2005, 39, 344.	1.1	1
100	Eighteen needles to forget…an unnamed past. Journal of Clinical Forensic and Legal Medicine, 2007, 14, 304-306.	0.5	1
101	Abdominal angina due to recurrence of cancer of the papilla of Vater: a case report. Journal of Medical Case Reports, 2009, 3, 9314.	0.4	1
102	Reply to: Liver injury caused by oral anticoagulants: A populationâ€based retrospective cohort study. Liver International, 2021, 41, 1435-1436.	1.9	1
103	Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World Journal of Gastroenterology, 2017, 23, 3195.	1.4	1
104	ECG signs of biatrial enlargement in a young adult. Internal and Emergency Medicine, 2010, 5, 441-442.	1.0	0
105	A peculiar cause of small-bowel intussusception and iron deficiency anaemia. Digestive and Liver Disease, 2011, 43, 171.	0.4	0
106	Comment on "The role of endoscopic ultrasound in the evaluation of chronic mesenteric ischaemia― Digestive and Liver Disease, 2012, 44, 86.	0.4	0
107	Vanishingâ€recurrent benign liver lesions. Liver International, 2014, 34, 1126-1126.	1.9	0
108	Etiopathogenesis of NAFLD: Diet, Gut, and NASH. , 2020, , 73-95.		0

## ANTONIO GRIECO

#	Article	IF	CITATIONS
109	Propafenone-related cholestatic hepatitis in an elderly patient. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2002, 3, 431-4.	0.1	0